Treatment of anxiety and depression in transplant patients: Pharmacokinetic considerations

Clinical Pharmacokinetics

Volumn 43, Issue 6, 2004, Pages 361-394

  Crone, Catherine C ^a   Gabriel, Geoffrey M ^b  

^a INOVA FAIRFAX HOSPITAL   (United States)

^b GEORGETOWN UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMFEBUTAMONE; AMINOGLYCOSIDE ANTIBIOTIC AGENT; AMITRIPTYLINE; BENZODIAZEPINE DERIVATIVE; CITALOPRAM; CLOMIPRAMINE; DIAZEPAM; ESCITALOPRAM; FLUOXETINE; FLUVOXAMINE; GABAPENTIN; IMMUNOSUPPRESSIVE AGENT; ISOCARBOXAZID; MIRTAZAPINE; MONOAMINE OXIDASE INHIBITOR; NEFAZODONE; NORFLUOXETINE; PAROXETINE; PHENELZINE; PSYCHOSTIMULANT AGENT; PSYCHOTROPIC AGENT; SELEGILINE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TRANYLCYPROMINE; TRAZODONE; TRICYCLIC ANTIDEPRESSANT AGENT; UNINDEXED DRUG; VENLAFAXINE; WARFARIN;

AGITATION; AGRANULOCYTOSIS; ANXIETY DISORDER; ATAXIA; BLEEDING; CARDIOVASCULAR EFFECT; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL; DEPRESSION; DIZZINESS; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG EXCRETION; DRUG HALF LIFE; DRUG METABOLISM; DRUG OVERDOSE; DRUG POTENTIATION; GASTROINTESTINAL SYMPTOM; GRAFT REJECTION; HEART VENTRICLE TACHYCARDIA; HUMAN; HYPERTENSION; HYPOTENSION; INSOMNIA; KIDNEY FAILURE; LIVER DISEASE; LIVER FAILURE; LIVER TOXICITY; LUNG DISEASE; NAUSEA; ORGAN TRANSPLANTATION; ORTHOSTATIC HYPOTENSION; PRIORITY JOURNAL; QT PROLONGATION; REBOUND; RESPIRATION DEPRESSION; RESTLESSNESS; REVIEW; SEDATION; SEIZURE; SIDE EFFECT; WEIGHT GAIN;

ANTI-ANXIETY AGENTS; ANTIDEPRESSIVE AGENTS; ANXIETY DISORDERS; DEPRESSION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; ORGAN TRANSPLANTATION; PREOPERATIVE CARE;

EID: 2342603988     PISSN: 03125963     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003088-200443060-00002     Document Type: Review

References (330)

1. Crone CC, Wise TN. Psychiatric aspects of transplantation: part II, preoperative issues. Crit Care Nurse 1999; 19: 51-63
2. Colon EA, Popkin MK. Anxiety and panic. In: Wise MG, Rundell JR, editors. The American Psychiatric Publishing textbook of consultation-liaison psychiatry: psychiatry in the medically ill. 2nd ed. Washington, DC: American Psychiatric Publishing, Inc 2002: 393-415
3. Rouchell AM, Pounds R, Tierney JG. Depression. In: Wise MG, Rundell JR, editors. The American Psychiatric Publishing textbook of consultation-liaison psychiatry: psychiatry in the medically ill. 2nd ed. Washington, DC: American Psychiatric Publishing Inc, 2002: 307-38
4. Beliles KE. Psychopharmacokinetics in the medically ill. In: Stoudemire A, Fogel BS, Greenberg DB, editors. Psychiatric care of the medical patient. New York (NY): Oxford, 2000: 373-394
5. Olyaei AJ, De Mattos AM, Bennett WM. Prescribing drugs in renal disease. In: Brenner BM, editor. The kidney, 6th ed. Philadelphia (PA): Saunders, 2000: 2606-53
6. Beliles K, Stoudemire A. Psychopharmacologic treatment of depression in the medically ill. Psychosomatics 1998; 39: S2-S19
7. Levy NB. Psychopharmacology in patients with renal failure. Int J Psychiatry Med 1990; 20: 325-34
8. Mann HJ, Fuhs DW, Cerra FB. Pharmacokinetics and pharmacodynamics in critically ill patients. World J Surg 1987; 11: 210-7
9. Maher JF. Pharmacokinetics in patients with renal failure. Clin Nephrol 1984; 21: 39-46
10. Kappel J, Calissi P. Nephrology: 3, safe drug prescribing for patients with renal insufficiency. CMAJ 2002 Feb 19; 166: 473-7
11. Matzke GR, Frye RF. Drug administration in patients with renal insufficiency: minimizing renal and extrarenal toxicity. Drug Saf 1997; 16: 205-31
12. Maher JF. Pharmacokinetic alterations with renal failure and dialysis. In: Chernow B, editor. The pharmacologic approach to the critically ill patient 2nd ed. Baltimore (MD): Williams & Wilkins, 1988: 47-68
13. Talbert RL. Drug dosing in renal insufficiency. J Clin Pharmacol 1994; 34: 99-110
14. Rubey RN, Lydiard RB. Pharmacologic treatment of anxiety in the medically ill patient. Semin Clin Neuropsychiatry 1999; 4: 133-47
15. Matzke GR, Frye RF. Drug administration in patients with renal insufficiency. Drug Saf 1997; 16: 205-31
16. Reichen J. Prescribing in liver disease. J Hepatol 1997; 26 Suppl. 1: 36-40
17. Rodighiero V. Effects of liver disease on pharmacokinetics: an update. Clin Pharmacokinet 1999; 37: 399-431
18. Verbeeck RK, Horsmans Y. Effects of hepatic insufficiency on pharmacokinetics and drug dosing. Pharm World Sci 1998; 20: 183-92
19. Arns PA, Wedlund PJ, Branch RA. Adjustment of medications in liver failure. In: Chernow B, editor. The pharmacologic approach to the critically ill patient 2nd ed. Baltimore (MD): Williams & Wilkins, 1988: 85-111
20. Morgan DJ, McLean AJ. Clinical pharmacokinetic and pharmacodynamic considerations in patients with liver disease: an update. Clin Pharmacokinet 1995; 29: 370-91
21. Adedoyin A, Branch RA. Pharmacokinetics. In: Zakim D, Boyer TD, editors. Hepatology: a textbook of liver disease. 3rd ed. Philadelphia (PA): Saunders, 1996: 307-22
22. Breimer DD. Pharmacokinetics in liver disease. Pharm Weekbl Sci 1987; 9: 79-84
23. Secor JW, Schenker S. Drug metabolism in patients with liver disease. Adv Intern Med 1987; 32: 379-406
24. Westphal JF, Brogard JM. Drug administration in chronic liver disease. Drug Saf 1997; 17: 47-73
25. Huet PM, Villeneuve JP, Fenyves D. Drug elimination in chronic liver diseases. J Hepatol 1997; 26 Suppl. 2: 63-72
26. Sonne J, Anderson PB, Loft S, et al. Glucuronidation of oxazepam is not spared in patients with hepatic encephalopathy. Hepatology 1990; 11: 951-6
27. Massie BM. Pathophysiology of heart failure. In: Goldman L, Bennett JC, editors. Cecil textbook of medicine. 21st ed. Philadelphia (PA): Saunders, 2000: 207-14
28. Williams RL, Benet LZ. Drug pharmacokinetics in cardiac and hepatic disease. Annn Rev Pharmacol Toxicol 1980; 20: 389-413
29. Shammas FV, Dickstein K. Clinical pharmacokinetics in heart failure: an update review. Clin Pharmacokinet 1988; 15: 94-113
30. Benowitz NL, Meister W. Pharmacokinetics in patients with cardiac failure. Clin Pharmacokinet 1976; 1: 389-405
31. Savage RW, Blair TP. Alterations in pharmacology caused by congestive heart failure in the critically ill patient. In: Chernow B, editor. The pharmacologic approach to the critically ill patient 2nd ed. Baltimore (MD): Williams & Wilkins, 1988: 69-84
32. Barre J, Houin G, Brunner F, et al. Disease-induced modifications of drug pharmacokinetics. Int J Clin Pharm Res 1983; 3: 215-26
33. Brater DC, Vasko MR. Pharmacokinetics. In: Chernow B, editor. The pharmacologic approach to the critically ill patient 2nd ed. Baltimore (MD): Williams & Wilkins, 1988: 1-20
34. DiMartini AF, Trzepacz PT. Psychopharmacologic issues in organ transplantation. In: Fukinishi I, Matsushita M, editors. Cutting-edge medicine and liaison psychiatry: psychiatric problems of organ transplantation. Proceedings of the 13th Toyko Institute of Psychiatry International Symposium; 1998 Sep 29-30; Toyko
35. Watson CB. Adjustment of medications in pulmonary failure. In: Chernow B, editor. The pharmacologic approach to the critically ill patient. 2nd ed. Baltimore (MD): Williams & Wilkins, 1988: 112-30
36. Rey E, Treluyer IM, Pons G. Drug disposition in cystic fibrosis. Clin Pharmacokinet 1998; 35: 313-29
37. Craven J. Psychiatric aspects of lung transplant: the Toronto Lung Transplant Group. Can J Psychiatry 1990; 35: 759-64
38. von Ammon Cavanaugh S. Depression in the medically ill: critical issues in diagnostic assessment. Psychosomatics 1995; 36: 48-59
39. Hinrichsen G, Lieberman J, Pollack S, et al. Depression in hemodialysis patients. Psychosomatics 1989; 30: 284-9
40. Rochat B, Amey M, Baumann P. Analysis of enantiomers of citalopram and its demethylated metabolites in plasma of depressive patients using chiral reverse-phase liquid chromatography. Ther Drug Monit 1995; 17: 273-9
41. von Moltke L, Greenblatt D, Grassi J, et al. Citalopram and desmethylcitalopram in vitro: human cytochromes mediating transformation and cytochrome inhibitory effects. Biol Psychiatry 1999; 46: 839-49
42. Rochat B, Amey M, Gillet M, et al. Identification of three cytochrome P450 isoenzymes involved in N-demethylation of citalopram enantiomers in human liver microsomes. Pharmacogenetics 1997; 7: 1-10
43. Baumann P, Larsen F. The pharmacokinetics of citalopram. Rev Contemp Pharmacother 1995; 6: 287-95
44. Kragh-Sorensen P, Overo K, Petersen O, et al. The kinetics of citalopram: single and multiple dose studies in man. Acta Pharmacol Toxicol 1981; 48 (1): 53-60
45. Baumann P. Pharmacology and pharmacokinetics of citalopram and other SSRIs. Int Clin Psychopharmacol 1996; 11 (1): 5-11
46. Greenblatt D, von Moltke L, Harmatz J, et al. Human cytochromes and some newer antidepressants: kinetics, metabolism, and drug interactions. J Clin Psychopharmacol 1999; 19 (1): 23-35
47. Beliles K. Alternate routes of administration of psychotropic agents. In: Stoudemire A, Fogel B, Greenberg D, editors. Psychiatric care of the medical patient. New York (NY): Oxford University Press, 2000: 395-405
48. Joffe P, Larsen F, Pedersen V, et al. Single-dose pharmacokinetics of citalopram in patients with moderate renal insufficiency or hepatic cirrhosis compared with healthy subjects. Eur J Clin Pharmacol 1998; 54: 237-42
49. Spigset O, Hagg S, Stegmayr B, et al. Citalopram pharmacokinetics in patients with chronic renal failure and the effect of haemodialysis. Eur J Clin Pharmacol 2000; 56: 699-703
50. Priskom M, Sidhu J, Larsen F, et al. Investigation of multiple dose citalopram on the pharmacokinetics and pharmacodynamics of racemic warfarin. Br J Clin Pharmacol 1997; 44: 199-202
51. Forest Pharmaceuticals Inc. Celexa® (citalopram): prescribing information. St Louis: Forest Pharmaceuticals Inc., 2002 Aug
52. Owens M, Knight D, Nemeroff C. Second-generation SSRIs: human monoamine transporter binding profile of escitalopram and R-flkuoxetine. Biol Psychiatry 2001; 50 (5): 345-50
53. Bauman P, Aullino D, Eap C. Enantiomers' potential in psychopharmacology: a critical analysis with special emphasis on the antidepressant escitalopram. Eur Neuropsychopharmacol 2002; 12: 433-44
54. Wade A, Lemming O, Bang Hedegaard K. Escitalopram 10 mg/ day is effective and well tolerated in a placebo-controlled study in depression in primary care. Int Clin Psychopharmacol 2002; 17: 95-102
55. Von Moltke L, Greenblatt D, Giancarlo G, et al. Eescitalopram (S-citalopram) and its metabolites in vitro: cytochromes mediating biotransormation, inhibitory effects, and comparison to R-citalopram. Drug Metab Disp 2001; 29: 1102-9
56. Guiterrez M, Rosenberg J, Abramowitz W. An evaluation of the potential for pharmacokinetic interaction between escitalopram and the cytochrome P450 3A4 inhibitor ritonavir. Clin Ther 2003; 25: 1200-10
57. Burke W. Escitalopram. Expert Opin Investig Drugs 2002; 11: 1477-86
58. Waugh J, Goa K. Escitalopram: a review of its use in the management of major depressive and anxiety disorder. CNS Drugs 2003; 17 (5): 343-62
59. Svensson S, Mansfield P. Escitalopram: superior to citalopram or a chiral chimera? Psychother Psychosom 2004; 73: 10-6
60. Murdoch D, McTavish D. Sertraline: a review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in depression and obsessive-compulsive disorder. Drugs 1992; 44: 604-24
61. Warrington S. Clinical implications of the pharmacology of sertraline. Int Clin Psychopharmacol 1991; 6 (2): 11-21
62. Warrington S, Ronfeld R, Wilner K, et al. Human pharmacokinetics of sertraline [letter]. Clin Neuropharmacol 1992; 15 (1): 54
63. Ozdemir V, Naranjo C, Herrmann N, et al. The extent and determinants of changes in CYP2D6 and CYP1A2 activities with therapeutic doses of sertraline. J Clin Psychopharmacol 1998; 18: 55-61
64. Crewe H, Lennard M, Tucker G, et al. The effect of selective serotonin re-uptake inhibitors on cytochrome P450 2D6 (CYP2D6) activity in human liver microsomes. Br J Clin Pharmacol 1992; 34: 262-5
65. Sprouse J, Clarke T, Reynolds L, et al. Comparison of the effects of sertraline and its metabolite, desmethylsertraline, on blockade of central 5-HT reuptake in vivo. Neuropsychopharmacology 1996; 14: 225-31
66. Kurz D, Bergstrom R, Goldberg M, et al. The effect of sertraline on the pharmacokinetics of desipramine and imipramine. Clin Pharmacol Ther 1997; 62: 145-56
67. Preskorn S, Alderman J, Greenblatt D, et al. Sertraline does not inhibit cytochrome P450 (CYP) 3A mediated drug metabolism in vivo. Biol Psychiatry 1997; 42 Suppl.: 45
68. Schwenk M, Verga M, Wagner J. Hemodialyzability of sertraline. Clin Nephrol 1995; 44: 121-4
69. Wilner K, Baris B, Foulds G. Multiple dose pharmacokinetics of sertraline in subjects with varying degrees of renal impairment. Eur Neuropsychopharmacol 1996; 6 Suppl.: 41
70. Demolis J, Angebaud P, Grange J, et al. Influence of liver cirrhosis on sertraline pharmacokinetics. Br J Clin Pharmacol 1996; 42: 394-7
71. Rapeport W, Coates P, Dewland P, et al. Absence of a sertraline-mediated effect on digoxin pharmacokinetic and electrocardiographic findings. J Clin Psychiatry 1996; 57 Suppl. 1: 16-9
72. Ziegler M, Wilner K. Sertraline does not alter the beta-adrenergic blocking activity of atenolol in healthy male volunteers. J Clin Psychiatry 1996; 57 Suppl. 1: 12-5
73. Wilner K, Lazar J, Apseloff G, et al. The effects of sertraline on the pharmacodynamics of warfarin in healthy volunteers. Biol Psychiatry 1991; 29: 354-5
74. Calhoun J, Calhoun D. Prolonged bleeding time in a patient treated with sertraline [letter]. Am J Psychiatry 1996; 153: 443
75. Dechant K. Paroxetine: a review. Drugs 1991; 41: 226-53
76. Lane R. Pharmacokinetic drug interaction potential of selective serotonin reuptake inhibitors. Int Clin Psychopharmacol 1996; 11 Suppl. 5: 31-61
77. Sindrup S, Brosen K, Gram L. Pharmacokinetics of the selective serotonin reuptake inhibitor paroxetine: nonlinearity and relation to the sparteine oxidation polymorphism. Clin Pharmacol Ther 1992; 51: 288-95
78. Jeppesen U, Gram L, Vistisen K, et al. Dose-dependent inhibition of CYP1A2, CYP2C19 and CYP2D6 by citalopram, fluoxetine, fluvoxamine and paroxetine. Eur J Clin Pharmacol 1996; 51: 73-8
79. DeVane C. Metabolism and pharmacokinetics of selective serotonin reuptake inhibitors. Cell Mol Neurobiol 1999; 19: 443-66
80. Doyle G, Laher M, Kelly J, et al. The pharmacokinetics of paroxetine in renal impairment. Acta Psychiatr Scand Suppl 1989; 350: 89-90
81. Krastev Z, Terziivanov D, Vlahov V, et al. The pharmacokinetics of paroxetine in patients with liver cirrhosis. Acta Psychiatr Scand Suppl 1989; 350: 91-2
82. Dalhoff K, Almdal T, Bjerrum K, et al. Pharmacokinetics of paroxetine in patients with cirrhosis. Eur J Clin Pharmacol 1991; 41: 351-4
83. Bannister S, Houser V, Hulse J, et al. Evaluation of the potential interactions of paroxetine with diazepam, cimetidine, warfarin, and digoxin. Acta Psychiatr Scand Suppl 1989; 350: 102-6
84. Gram L. Fluoxetine. N Engl J Med 1994; 331: 1354-61
85. Wong D, Bymaster F, Reid L, et al. Inhibition of serotonin uptake by optical isomers of fluoxetine. Drug Dev Res 1985; 6: 397-403
86. Hamelin B, Turgeon J, Vallee F, et al. The disposition of fluoxetine but not sertraline is altered in poor metabolizers of debrisoquin. Clin Pharmacol Ther 1996; 60: 512-21
87. von Moltke L, Greenblatt D, Duan S, et al. Human cytochromes mediating N-demethylation of fluoxetine in vitro. Psychopharmacology 1997; 132: 402-7
88. Harvey A, Preskorn S. Fluoxetine pharmacokinetics and effect on CYP2C19 in young and elderly volunteers. J Clin Psychopharmacol 2001; 21: 161-6
89. Riesenman C. Antidepressant drug interactions and the cytochrome P450 system: a critical appraisal. Pharmacotherapy 1995; 15: 84-99
90. Altamura A, Moro A, Percudani M. Clinical pharmacokinetics of fluoxetine. Clin Pharmacokinet 1994; 26: 201-14
91. Benefield P, Heel R, Lewis S. Fluoxetine: a review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in depressive illness. Drugs 1986; 32: 481-508
92. Bergstron R, Lemberger L, Farid N, et al. Clinical pharmacology and pharmacokinetics of fluoxetine: a review. Br J Psychiatry 1988; 153 Suppl. 3: 47-50
93. Aronoff G, Bergstrom R, Pottratz S, et al. Fluoxetine kinetics and protein binding in normal and impaired renal function. Clin Pharmacol Ther 1984; 36: 138-44
94. Bergstrom R, Beasely C, Levy N, et al. The effects of renal and hepatic disease on the pharmacokinetics, renal tolerance, and risk-benefit profile of fluoxetine. Int Clin Psychopharmacol 1993; 8: 261-6
95. Schenker S, Bergstrom R, Wolen R, et al. Fluoxetine disposition and elimination in cirrhosis. Clin Pharmacol Ther 1988; 44: 353-9
96. Graff D, Williamson K, Pieper J, et al. Effect of fluoxetine on carvedilol pharmacokinetics, CYP2D6 activity, and autonomic balance in heart failure patients. J Clin Pharmacol 2001; 41: 97-106
97. Ring B, Binkley S, Roskos L, et al. Effect of fluoxetine, norfluoxetine, sertraline, and desmethylsertraline on human CYP3A catalyzed 1-hydroxy midazolam formation in vitro. J Pharmacol Exp Ther 1995; 275: 1131-5
98. Azaz-Livshits T, Danenberg H. Tachycardia, orthostatic hypotension and profound weakness due to concomitant use of fluoxetine and nifedipine. Pharmacopsychiatry 1997; 30: 274-5
99. Lemberger L, Bergstrom R, Wolen R, et al. Fluoxetine: clinical pharmacology and physiological disposition. J Clin Psychiatry 1985; 46: 14-9
100. Pai V, Kelly M. Bruising associated with the use of fluoxetine. Ann Pharmacother 1996; 30: 786-8
101. Bondurant T, Darrell M, Asyouty S, et al. The effect of fluoxetine on prothrombin time [letter]. Psychosomatics 1998; 39: 296-8
102. Van Harten J. Overview of the pharmacokinetics of fluvoxamine. Clin Pharmacokinet 1995; 29 Suppl. 1: 1-9
103. Spigset O, Carleborg L, Hedenmalm K, et al. Effect of cigarette smoking on fluvoxamine pharmacokinetics in humans. Clin Pharmacol Ther 1995; 58: 399-403
104. Brosen K, Skielbo E, Rasmussen B, et al. Fluvoxamine is a potent inhibitor of cytochrome P4501A2. Biochem Pharmacol 1993; 45: 1211-4
105. Wang J, Backman J, Wen X, et al. Fluvoxamine is a more potent inhibitor of lidocaine metabolism than ketoconazole and erythromycin in vitro. Pharmacol Toxicol 1999; 85: 201-5
106. Overmars H, Scherpenisse P, Post L. Fluvoxamine maleate: metabolism in man. Eur J Drug Metab Pharmacokinet 1983; 8: 269-80
107. De Vries M, Raghoebar M, Mathlener I, et al. Single and multiple oral dose fluvoxamine kinetics in young and elderly subjects. Ther Drug Monit 1992; 14: 291-6
108. Spigset O, Granberg K, Hagg S, et al. Non-linear fluvoxamine disposition. Br J Clin Pharmacol 1998; 45: 257-63
109. Benfield P, Ward A. Fluvoxamine: a review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in depressive illness. Drugs 1986; 32: 313-34
110. Claassen V. Review of the animal pharmacology and pharmacokinetics of fluvoxamine. Br J Clin Pharmacol 1983; 15 Suppl. 3: 349-55
111. van Harten J, Duchier J, Devissaguet J, et al. Pharmacokinetics of fluvoxamine maleate in patients with liver cirrhosis after single-dose oral administration. Clin Pharmacokinet 1993; 24: 177-82
112. Dahl M, Voortman G, Alm C, et al. In vitro and in vivo studies on the disposition of mirtazapine in humans. Clin Drug Invest 1997; 13: 37-46
113. Stromer E, von Moltke L, Shader R, et al. Metabolism of the antidepressant mirtazapine in vitro: contribution of cytochromes P-450 1A2, 2D6, and 3A4. Drug Metab Dispos 2000; 28: 1168-75
114. Timmer J, Sitsen J, Delbressine L. Clinical pharmacokinetics of mirtazapine. Clin Pharmacokinet 2000; 38: 461-74
115. Delbressine L, Vos R. The clinical relevance of preclinical data: mirtazapine, a model compound. J Clin Psychopharmacol 1997; 17 Suppl. 1: 29-34
116. Sitsen J, Zivkov M. Mirtazapine: clinical profile. CNS Drugs 1995; 4 Suppl.: 39-48
117. Timmer C, Lohmann A, Mink C. Pharmacokinetic dose-proportionality study at steady state of mirtazapine from Remeron tablets. Hum Psychopharmacol 1995; 10 Suppl.: 97-106
118. Voortman G, Paanakker J. Bioavailabilty of mirtazapine from Remeron tablets after single and multiple oral dosing. Hum Psychopharmacol 1995; 10 Suppl.: 83-96
119. Bengtsson F, Hoglund P, Timmer C, et al. Mirtazapine oral single dose kinetics in patients with different degrees of renal failure. Hum Psychopharmacol Clin Exp 1998; 13: 357-65
120. Murdoch D, Ashgar J, Ankier S, et al. Influence of hepatic impairment on the pharmacokinetics of single doses of mirtazapine in elderly subjects [abstract]. Br J Clin Pharmacol 1993; 35: 76
121. Nilsen O, Dale O. A pharmacokinetic study of trazodone in healthy subjects after intravenous, fasted and not fasted oral administration. Pharmacol Toxicol 1992; 71: 150-3
122. Rotzinger S, Fang J, Baker G. Trazodone is metabolized to m-chlorophenylpiperazine by CYP3A4 from human sources. Drug Metab Dispos 1998; 26: 572-5
123. Bayer A, Pathy M, Ankier S. Pharmacokinetic and pharmacodynamic characteristics of trazodone in the elderly. Br J Clin Pharmacol 1983; 16: 371-6
124. Haria M, Fitton A, McTavish D. Trazodone: a review of its pharmacology, therapeutic use in depression and therapeutic potential in other disorders. Drugs Aging 1994; 4: 331-5
125. Yasui N, Otani K, Kaneko S, et al. Inhibition of trazodone metabolism by thioridazine in humans. Ther Drug Monit 1995; 17: 333-5
126. Doweiko J, Fogel B, Godlberg R. Trazodone and hemodialysis [letter]. J Clin Psychiatry 1984; 45: 361
127. Gamble D, Peterson L. Trazodone overdose: four years of experience from voluntary reports. J Clin Psychiatry 1986; 47: 544-6
128. Trujillo T, Nolan P. Antiarrhythmic agents: drug interactions of clinical significance. Drug Saf 2000; 23: 509-32
129. Mazur A, Strasberg B, Kusniec J, et al. OT prolongation and polymorphous ventricular tachycardia associated with trazodone-amiodarone combination. Int J Cardiol 1995; 52: 27-9
130. Small N, Giamonna K. Interaction between warfarin and trazodone. Ann Pharmacother 2000; 34: 734-6
131. Hardy J, Sirois A. Reduction of prothrombin and partial thromboplastin times with trazodone [case report]. CMAJ 1986; 135: 1372
132. Eison A, Eison M, Torrente J, et al. Nefazodone: preclinical pharmacology of a new antidepressant. Psychopharmacol Bull 1990; 26: 311-5
133. Mayol R, Cole C, Luke G, et al. Characterization of the metabolites of the antidepressant drug nefazodone in human urine and plasma. Drug Metab Dispos 1994; 22: 304-11
134. DeVane L, Grothe D, Smith S. Pharmacology of antidepressants: focus on nefazodone. J Clin Psychiatry 2002; 63 Suppl.: 10-7
135. Barbhaiya R, Buch A, Greene D. Single and multiple dose pharmacokinetics of nefazodone in subjects classified as extensive and poor metabolizers of dextromethorphan. Br J Clin Pharmacol 1996; 42: 573-81
136. 14C]nefazodone in humans. Drug Metab Dispos 1996; 24: 91-5
137. Kaul S, Shukla U, Barbhaiya R. Nonlinear pharmacokinetics of nefazodone after escalating single and multiple oral doses. J Clin Pharmacol 1995; 35: 830-9
138. Bristol-Myers Squibb. Serzone® (nefazodone): prescribing information. Princeton (NJ): Bristol-Myers Squibb Company, 2000
139. Barbhaiya R, Brady M, Shukla U, et al. Steady state pharmacokinetics of nefazodone in subjects with normal and impaired renal function. Eur J Clin Pharmacol 1995; 49: 229-35
140. Barbhaiya R, Shukla U, Greene D. Single-dose pharmacokinetics of nefazodone in healthy young and elderly subjects and in subjects with renal or hepatic impairment. Eur J Clin Pharmacol 1995; 49: 221-8
141. Barbhaiya R, Shukla U, Natarajan C, et al. Single-and multiple-dose pharmacokinetics of nefazodone in patients with hepatic cirrhosis. Clin Pharmacol Ther 1995; 58: 390-8
142. Salazar D, Dockens R, Milbrath R, et al. Pharmacokinetic and pharmacodynamic evaluation of warfarin and nefazodone coadministration in healthy subjects. J Clin Pharmacol 1995; 35: 730-8
143. Dockens R, Greene D, Barbhaiya R. Assessment of pharmacokinetic and pharmacodynamic drug interactions between nefazodone and digoxin in healthy male volunteers. J Clin Pharmacol 1996; 36: 160-7
144. Jacobson R, Wang P, Glueck C. Myositis and rhabdomyolysis associated with concurrent use of simvastatin and nefazodone [letter]. JAMA 1997; 277: 296-7
145. Aranda-Michel J, Koehler A, Bejarano P, et al. Nefazodone-induced liver failure: report of three cases. Arch Intern Med 1999; 130: 285-8
146. Lucena M, Andrade R, Gomez-Outes A, et al. Acute liver failure after treatment with nefazodone. Dig Dis Sci 1999; 44: 2577-9
147. Eloubeidi M, Gaede J, Swaim M. Reversible nefazodone-induced liver failure. Dig Dis Sci 2000; 45: 1036-8
148. Golden R, DeVane C, Laizure S, et al. Bupropion in depression: II. the role of metabolites in clinical outcome. Arch Gen Psychiatry 1988; 45: 145-9
149. Ascher J, Cole J, Colin J, et al. Bupropion: a review of its mechanism of antidepressant activity. J Clin Psychiatry 1996; 56: 395-401
150. Martin P, Massol J, Colin J, et al. Antidepressant profile of bupropion and three metabolites in mice. Pharmacopsychiatry 1990; 23: 187-94
151. Armstrong S, Cozza K. Does bupropion inhibit cytochrome P450 2D6? Psychosomatics 2001; 42: 157-9
152. DeVane L, Nemeroff C. 2002 Guide to psychotropic drug interactions. Primary Psychiatry 2002; 9: 28-57
153. Hesse L, Venkatakrishnan K, Court M, et al. CYP2B6 mediates the in vitro hydroxylation of bupropion: potential drug interactions with other antidepressants. Drug Metab Dispos 2000; 28: 1176-83
154. Pollock B, Sweet R, Kirshner M, et al. Bupropion plasma levels and CYP2D6 phenotype. Ther Drug Monit 1996; 18: 581-5
155. Lai A, Schroeder D. Clinical pharmacokinetics of bupropion: a review. J Clin Psychiatry 1983; 44: 82-4
156. Goodnick P. Pharmacokinetics of second generation antidepressants: bupropion. Psychopharmacol Bull 1991; 27: 513-9
157. Goodnick P, Dominguez R, DeVane L, et al. Bupropion slow-release response in depression: diagnosis and biochemistry. Biol Psychiatry 1998; 44: 629-32
158. Sweet R, Pollock B, Kirshner M, et al. Pharmacokinetics of single- and multiple-dose bupropion in elderly patients with depression. J Clin Pharmacol 1995; 35: 876-84
159. DeVane L, Laizure C, Stewart J, et al. Disposition of bupropion in healthy volunteers and subjects with alcoholic liver disease. J Clin Psychopharmacol 1990; 10: 328-32
160. Roose S, Dalack G, Glassman A, et al. Cardiovascular effects of bupropion in depressed patients with heart disease. Am J Psychiatry 1991; 148: 512-6
161. Fogelman S, Schimider J, Venkatakrishnan K, et al. O- and N-demethylation of venlafaxine in vitro by human liver microsomes and by microsomes from cDNA-transfected cells: effect of metabolic inhibitors and SSRI antidepressants. Neuropsychopharmacology 1999; 20: 480-90
162. Otton S, Ball S, Cheung S, et al. Venlafaxine oxidation in vitro is catalysed by CYP2D6. Br J Clin Pharmacol 1996; 41: 149-56
163. Amchin J, Zarycranski W, Taylor K, et al. Effect of venlafaxine on the pharmacokinetics of risperidone. J Clin Pharmacol 1999; 39: 297-309
164. von Moltke L, Duan S, Greenblatt D, et al. Venlafaxine and metabolites are very weak inhibitors of human cytochrome P450-3A isoforms. Biol Psychiatry 1997; 41: 377-80
165. Ereshefsky L. Drug-drug interactions involving antidepressants: focus on venlafaxine. J Clin Psychopharmacol 1996; 16 (3 Suppl. 2): 37-53
166. Artigas F. Selective serotonin/noradrenaline reuptake inhibitors (SNRIs). CNS Drugs 1995; 4: 79-89
167. Morton W, Soone S, Verga M. Venlafaxine: a structurally unique and novel antidepressant. Ann Pharmacother 1995; 29: 387-95
168. Troy S, Schultz R, Parker V, et al. The effect of renal disease on the disposition of venlafaxine. Clin Pharmacol Ther 1994; 56: 14-21
169. Wellington K, Perry C. Venlafaxine extended release: a review of its use in the management of major depression. CNS Drugs 2001; 15: 543-669
170. Feighner J. Cardiovascular safety in depressed patients: focus on venlafaxine. J Clin Psychiatry 1995; 56: 574-9
171. Simmer B, Kant R, Zeiler D, et al. Antidepressant efficacy and cardiovascular safety of venlafaxine in young vs old patients with comorbid medical disorders. Int J Psychiatry Med 1997; 27: 353-64
172. Blythe D, Hackett L. Cardiovascular and neurological toxicity of venlafaxine. Hum Exp Toxicol 1999; 18: 309-13
173. Combs A, Peytavin G, Theron D. Conduction disturbances associated with venlafaxine [letter]. Ann Intern Med 2001; 134: 166-7
174. Partridge S, MacIver D, Solanki T. A depressed myocardium. Clin Toxicol 2000; 38: 453-5
175. Thase M. Effects of venlafaxine on blood pressure: a metaanalysis of original data from 3744 depressed patients. J Clin Psychiatry 1998; 59: 502-8
176. Horsmans Y, DeClercq M, Sempoux C. Venlafaxine-associated hepatitis [letter]. Ann Intern Med 1999; 130: 944
177. Cardona X, Avila A, Castellanos P. Venlafaxine-associated hepatitis [letter]. Ann Intern Med 2000; 132: 417
178. American Psychiatric Association. Practice guidelines for the treatment of patients with major depressive disorder (revision). Am J Psychiatry 2000; 157 (11 Suppl.): 1-45
179. Bodkin J, Kwon A. Selegiline and other atypical monoamine oxidase inhibitors in depression. Psychiatr Ann 2001; 31: 385-91
180. Mallinger A, Smith E. Pharmacokinetics of monoamine oxidase inhibitors. Psychopharmacol Bull 1991; 27: 493-502
181. Volz H, Gleiter C. Monoamine oxidase inhibitors: a perspective on their use in the elderly. Drugs Aging 1998; 13: 341-55
182. Mallinger A, Edwards D, Himmelhoch J, et al. Pharmacokinetics of tranylcypromine in patients who are depressed: relationship to cardiovascular effects. Clin Pharmacol Ther 1986; 40: 444-50
183. Baker G, Urichuk L, McKenna K, et al. Metabolism of monoamine oxidase inhibitors. Cell Mol Neurobiol 1999; 19: 411-26
184. Grace J, Kinter M, MacDonald T. Atypical metabolism of deprenyl and its enantiomer, (S)-(+)-N,α-dimethyl-N-propynylphenethylamine, by cytochrome P450 2D6. Chem Res Toxicol 1994; 7: 286-90
185. Livingston M, Livingston H. Monoamine oxidase inhibitors: an update on drug interactions. Drug Saf 1996; 14: 219-27
186. Brown T, Stoudemire A, Fogel B, et al. Psychopharmacology in the medical patient. In: Stoudemire A, Fogel B, Greenberg D, editors. Psychiatric care of the medical patient. New York (NY): Oxford University Press, 2000; 329-72
187. Thompson D, DiMartini A. Nonenteral routes of administration for psychiatric medications. Psychosomatics 1999; 40: 185-92
188. Rudorfer M, Potter W. Metabolism of the tricyclic antidepressants. Cell Mol Neurobiol 1999; 19: 373-409
189. Potter W, Manji H, Rudorfer M. Tricyclics and tetracyclics. In: Schatzberg A, Nemeroff C, editors. Essentials of clinical psychopharmacology. Washington, DC: American Psychiatric Publishing Inc, 2001: 5-26
190. Rudorfer M, Potter W. Pharmacokinetics of antidepressants. In: Meltzer H, editor. Psychopharmacology: the third generation of progress. New York (NY): Raven Press, 1987: 1353-63
191. Sandoz M, Vandel S, Vandel B, et al. Metabolism of amitriptyline in patients with chronic renal failure. Eur J Clin Pharmacol 1984; 26: 227-32
192. Lieberman J, Cooper T, Suckow R, et al. Tricyclic antidepressant and metabolite levels in chronic renal failure. Clin Pharmacol Ther 1985; 37: 301-7
193. Dawling S, Lynn K, Rosser R, et al. The pharmacokinetics of nortriptyline in patients with chronic renal failure. Br J Clin Pharmacol 1981; 12: 39-45
194. Forycki Z, Martens F, Thalhofer K. Tranquilizers, analgetics and antidepressants in patients treated with hemodialysis. Blood Purif 1985; 3: 109-19
195. Brosen K, Gram L. Quinidine inhibits the 2-hydroxylation of imipramine and desipramine but not demethylation of imipramine. Eur J Clin Pharmacol 189; 37: 155-60
196. Kaufmann M, Murray G, Cassem N. Use of psychostimulants in medically ill depressed patients. Psychosomatics 1982; 23: 817-9
197. Woods S, Tesar G, Murray G, et al. Psychostimulant treatment of depressive disorders secondary to medical illness. J Clin Psychiatry 1986; 47: 12-5
198. Masand P, Tesar G. Use of stimulants in the medically ill. Psychiatr Clin North Am 1996; 19: 515-47
199. Srinivas N, Hubbard J, Quinn D, et al. Enantio-selective pharmacokinetics and pharmacodynamics of dl-threo-methylphenidate in children with attention deficit hyperactivity disorder. Clin Pharmacol Ther 1992; 52: 561-8
200. Wargin W, Patrick K, Kilts C, et al. Pharmacokinetics of methylphenidate in man, rat, and monkey. J Pharmacol Exp Ther 1983; 226: 382-6
201. Angrist B, Corwin J, Bartlik B, et al. Early pharmacokinetics and clinical effects of oral d-amphetamine in normal subjects. Biol Psychiatry 1987; 22: 1357-68
202. De Batista C, Lembke A, Solvason HB, et al. A prospective trial of modafinil as an adjunctive treatment of major depression. J Clin Psychopharmacol 2004; 24: 87-90
203. Wong Y, Simcoe D, Hartman L, et al. A double-blind, placebo-controlled, ascending-dose evaluation of the pharmacokinetics and tolerability of modafinil tablets in healthy male volunteers. J Clin Pharmacol 1999; 39: 30-40
204. McClellan K, Spencer C. Modafinil: a review of its pharmacology and clinical efficacy in the management of narcolepsy. CNS Drugs 1998; 9: 311-24
205. Cox J, Pappagallo M. Modafinil: a gift to portmanteau. Am J Hosp Palliat Care 2001; 18: 408-10
206. McCurry L, Cronquist S. Pemoline and hepatoxicity [letter]. Am J Psychiatry 1997; 154: 713-4
207. Safer D, Zito J, Gardner J. Pemoline hepatoxicity and postmarketing surveillance. J Am Acad Child Adolesc Psychiatry 2001; 40: 622-9
208. Shevell M, Schreiber R. Pemoline-associated hepatic failure: a critical analysis of the literature. Pediatr Neurol 1997; 16: 14-6
209. Plutchik L, Synder S, Drooker M, et al. Methylphenidate in post liver transplant patients. Psychosomatics 1998; 39: 118-23
210. Wright D, Lake K, Bruhn P, et al. Nefazodone and cyclosporine drug-drug interaction. J Heart Lung Transplant 1999; 18: 913-5
211. Vella J, Sayegh M. Interactions between cyclosporine and newer antidepressant medications. Am J Kidney Dis 1998; 31: 320-2
212. Helms-Smith KM, Curtis SL. Apparent interaction between nefazodone and cyclosporine [letter]. Ann Intern Med 1996; 125: 424
213. Lill J, Bauer L, Horn J, et al. Cyclosporine-drug interactions and the influence of patient age. Am J Health Syst Pharm 2000; 57: 1579-84
214. Markowitz JS, Gill HS, Hunt NM, et al. Lack of antidepressant- cyclosporine pharmacokinetic interactions. J Clin Psychopharmacol 1998; 18: 91-3
215. Liston H, Markowitz J, Hunt N, et al. Lack of citalopram effect on the pharmacokinetics of cyclosporine [letter]. Psychosomatics 2001; 42: 370-2
216. Strouse T, Fairbanks L, Skotzko C, et al. Fluoxetine and cyclosporine in organ transplantation. Psychosomatics 1996; 37: 23-30
217. Cakaloglu Y, Tredger J, Devlin J, et al. Importance of cytochrome P-450IIIA activity in determining dosage and blood levels of FK506 and cyclosporine in liver transplant recipients. Hepatology 1994; 20: 309-16
218. Campo J, Smith C, Perel J. Tacrolimus toxic reaction associated with the use of nefazodone: paroxetine as an alternative agent [letter]. Arch Gen Psychiatry 1998; 55: 1050-2
219. Olyaei AJ, deMattos AM, Norman DJ, et al. Interaction between tacrolimus and nefazodone in a stable renal transplant recipient. Pharmacotherapy 1998; 18: 1356-9
220. Yatscoff R. Pharmacokinetics of rapamycin. Transplant Proc 1996; 28: 970-3
221. Zimmerman J, Kahan B. Pharmacokinetics of sirolimus in stable renal transplant patients after multiple oral dose administration. J Clin Pharmacol 1997; 37: 405-15
222. Yatscoff R, Wang P, Chan K, et al. Rapamycin: distribution, pharmacokinetics, and therapeutic range investigations. Ther Drug Monit 1995; 17: 666-71
223. Lampen A, Ahang Y, Hackbarth I, et al. Metabolism and transport of the macrolide immunosuppressant sirolimus in the small intestine. J Pharmacol Exp Ther 1998; 285: 1104-12
224. Claesson K, Brattstrom C, Burke J. Sirolimus interaction: first report of an interaction with concomitant erythromycin leading to an increased sirolimus concentration [case report]. Transplant Proc 2001; 33: 2136
225. Bullingham R, Nicholls A, Kamm B. Clinical pharmacokinetics of mycophenolate mofetil. Clin Pharmacokinet 1998; 34: 429-55
226. Trumper A, Appleby L. Psychiatric morbidity in patients undergoing heart, heart and lung, or lung transplantation. J Psychosom Res 2001; 50: 103-5
227. Taylor CB. Treatment of anxiety disorders. In: Schatzberg AF, Nemeroff CB, editors. Essentials of clinical psychopharmacology. Washington, DC: American Psychiatric Publishing Inc, 2001: 431-45
228. Davis LI, English BA, Ambrose SM, et al. Pharmacotherapy for post-traumatic stress disorder: a comprehensive review. Expert Opin Pharmacother 2001; 2: 1583-95
229. Chouinard G, Lefko-Singh K, Teboul E. Metabolism of anxiolytics and hypnotics: benzodiazepines, buspirone, zoplicone, and zolpidem. Cell Mol Neurobiol 1999; 19: 533-52
230. Brown TM, Stoudemire A, Fogel BS, et al. Psychopharmacology in the medically ill. In: Stoudemire A, Fogel BS, Greenberg DB, editors. Psychiatric care of the medical patient. New York (NY): Oxford, 2000: 329-72
231. Garzone PD, Kroboth PD. Pharmacokinetics of the newer benzodiazepines. Clin Pharmacokinet 1989; 16: 337-64
232. Tiula E, Tallgren LG, Neuvonen PJ. Serum protein binding of phenytoin, diazepam, and propanolol in chronic renal diseases. Int J Clin Pharmacol Ther Toxicol 1987; 25: 545-52
233. Wagner BKJ, O'Hara DA. Pharmacokinetics and pharmacodynamics of sedatives and analgesics in the treatment of agitated critically ill patients. Clin Pharmacokinet 1997; 33: 426-53
234. Bauer TM, Ritz R, Haberthur C, et al. Prolonged sedation due to accumulation of conjugated metabolites of midazolam. Lancet 1995; 346: 145-7
235. Bouton V, Bourget P, Lesne-Hulin A, et al. Influence of acute renal failure on FPIA rapid serum assay of midazolam and its main metabolite. Int J Clin Pharmacol Ther 1997; 35: 531-8
236. Messen JJ, Vree TB, Guelen PJM. The effects of acute changes in renal function on the pharmacokinetics of midazolam during long-term infusion in ICU patients. Acta Anaesth Belg 1991; 42: 149-55
237. Kyriakopoulos AA, Greenblatt DJ, Shader RI. Clinical pharmacokinetics of lorazepam: a review. J Clin Psychiatry 1978; 10: 16-23
238. Kraus JW, Desmond PV, Marshall JP, et al. Effects of aging and liver disease on disposition of lorazepam. Clin Pharmacol Ther 1978; 24: 411-9
239. Shull HJ, Wilkinson GR, Johnson R, et al. Normal disposition of oxazepam in acute viral hepatitis and cirrhosis. Ann Intern Med 1976; 84: 420-5
240. Man GCW, Hsu K, Sproule BJ. Effect of alprazolam on exercise and dyspnea in patients with chronic obstructive pulmonary disease. Chest 1986; 90: 832-6
241. Greene JG, Pucino F, Carlson JD, et al. Effects of alprazolam on respiratory drive, anxiety, and dyspnea in chronic airflow obstruction: a case study. Pharmacotherapy 1989; 9: 34-8
242. Cohn MA, Morris DD, Juan D. Effects of estazolam and flurazepam on cardiopulmonary function in patients with chronic obstructive pulmonary disease. Drug Saf 1992; 7: 152-8
243. Sen D, Jones G, Leggat PO. The response of the breathless patient treated with diazepam. Br J Clin Pract 1983 Jun; 37 (6): 232-3
244. 2 chemosensitivity in patients with lung diseases. Respiration 1981; 42: 15-20
245. Beaupre A, Soucy R, Phillips R, et al. Respiratory center output following zopliclone or diazepam administration in patients with pulmonary disease. Respiration 1988; 54: 235-40
246. Wedzicha JA, Wallis PJW, Ingram DA, et al. Effect of diazepam on sleep in patients with chronic airflow obstruction. Thorax 1988; 43: 729-30
247. Woodcock AA, Gross ER, Geddes DM. Drug treatment of breathlessness: contrasting effects of diazepam and promethazine in pink puffers. BMJ 1981; 283: 343-6
248. Block AH, Dolly FR, Slayton PC. Does flurazepam ingestion affect breathing and oxygenation during sleep in patients with chronic obstructive lung disease? Am Rev Respir Dis 1984; 129: 230-3
249. Ninan PT, Cole JO, Yonkers KA. Nonbenzodiazepine anxiolytics. 1st ed. In: Schatzberg AF, Nemeroff CB, editors. Essentials of clinical psychopharmacology. Washington DC: American Psychiatric Publishing Inc, 2001: 93-102
250. Mahmood I, Sahajwalla C. Clinical pharmacokinetics and pharmacodynamics of buspirone, an anxiolytic drug. Clin Pharmacokinet 1999; 36: 277-87
251. Apter JT, Allen LA. Buspirone: future directions. J Clin Psychopharmacol 1999; 19: 86-93
252. Ninan PT, Cole JO, Yonkers KA. Nonbenzodiazepine anxiolytics. In: Schatzberg AF, Nemeroff CB, editors. Essentials of clinical psychopharmacology. Washington, DC: American Psychiatric Publishing Inc, 2001: 93-102
253. Argyropoulou P, Patakas D, Koukou A, et al. Buspirone effect on breathlessness and exercise performance in patients with chronic obstructive pulmonary disease. Respiration 1993; 60: 216-20
254. Alderman CP, Frith PA, Ben-Tovim DI. Buspirone for the treatment of anxiety in patients with chronic obstructive airways disease. J Clin Psychopharmacol 1996; 16: 410-1
255. Craven J, Sutherland A. Buspirone for anxiety disorders in patients with severe lung disease [letter]. Lancet 1991; 338: 249
256. Singh NP, Despars JA, Stansbury DW, et al. Effects of buspirone on anxiety levels and exercise tolerance in patients with chronic airflow obstruction and mild anxiety. Chest 1993; 103: 800-4
257. Caccia S, Vigano GL, Mingardi G, et al. Clinical pharmacokinetics of oral buspirone in patients with impaired renal function. Clin Pharmacokinet 1988; 14: 171-7
258. Barbhaiya RH, Shukla UA, Pfeffer M, et al. Disposition kinetics of buspirone in patients with renal or hepatic impairment after administration of single and multiple doses. Eur J Clin Pharmacol 1994; 46: 41-7
259. Dalhoff K, Poulsen HE, Garred P, et al. Buspirone pharmacokinetics in patients with cirrhosis. Br J Clin Pharmacol 1987; 24: 547-50
260. Lamberg TS, Kivisto KT, Laitila J, et al. The effect of fluvoxamine on the pharmacokinetics and pharmacodynamics of buspirone. Eur J Clin Pharmacol 1998; 54: 761-6
261. Lamberg TS, Kivisto KT, Neuvonen PJ. Effects of verapamil and diltiazem on the pharmacokinetics and pharmacodynamics of buspirone. Pharmacol Ther 1998; 63: 640-5
262. Letterman L, Markowitz JS. Gabapentin: a review of published experience in the treatment of bipolar disorder and other psychiatric conditions. Pharmacotherapy 1999; 19: 565-72
263. Pande AC, Davidson JR, Jefferson JW, et al. Treatment of social phobia with gabapentin: a placebo-controlled study. J Clin Psychopharmacol 1999; 19: 341-8
264. Pollack MH, Methews J, Scott EL. Gabapentin as a potential treatment for anxiety disorders. Am J Psychiatry 1998; 155: 992-3
265. Brannon N, Labbate L, Huber M. Gabapentin treatment for posttraumatic stress disorder [letter]. Can J Psychiatry 2000 Feb; 45 (1): 84
266. Hamner MB, Brodrick PS, Labbate LA. Gabapentin in PTSD: a retrospective, clinical series of adjunctive therapy. Ann Clin Psychiatry 2001; 13: 141-6
267. Chouinard G, Beauclair L, Belanger MC. Gabapentin: long-term antianxiety and hypnotic effects in psychiatric patients with comorbid anxiety-related disorders [letter]. Can J Psychiatry 1998; 43: 305
268. Hood SD, Argyropoulos SV, Nutt DJ. Agents in development for anxiety disorders: current status and future potential. CNS Drugs 2000; 13: 421-31
269. Gallay BJ, DeMattos AM, Norman DJ. Reversible acute renal allograft dysfunction due to gabapentin. Transplantation 2000; 70: 208-9
270. Grunze H, Dittert S, Bungert M, et al. Renal impairment as a possible side effect of gabapentin: a single case report. Neuropsychobiology 1998; 38: 198-9
271. Bourgeois BFD. Pharmacokinetic properties of current antiepileptic drugs: what improvements are needed? Neurology 2000; 55 Suppl. 3: S11-6
272. Blum RA, Comstock TJ, Sica DA, et al. Pharmacokinetics of gabapentin in subjects with various degrees of renal function. Clin Pharmacol Ther 1994; 56: 154-9
273. Masand PS, Gupta S. Selective serotonin-reuptake inhibitors: an update. Harv Rev Psychiatry 1999; 7: 69-84
274. Ballenger JC, Davidson JRT, Lecrubier Y, et al. Consensus statement on panic disorder from the International Consensus Group on Depression and Anxiety. J Clin Psychiatry 1998; 59 Suppl. 8: 47-54
275. Lecrubier Y, Bakker A, Dunbar G, et al. A comparison of paroxetine, clomipramine and placebo in the treatment of panic disorder. Acta Psychiatr Scand 1997; 95: 145-52
276. Oehrberg PE, Christiansen K, Behnke AL, et al. Paroxetine in the treatment of panic disorder: a randomized, double-blind, placebo-controlled study. Br J Psychiatry 1995; 167: 374-9
277. Ballenger JC, Wheadon DE, Steiner M, et al. Double-blind, fixed-dose, placebo-controlled study of paroxetine in the treatment of panic disorder. Am J Psychiatry 1998; 155: 36-42
278. Wade AG, Lepola U, Koponen J, et al. The effect of citalopram in panic disorder. Br J Psychiatry 1997; 170: 549-53
279. Lepola UM, Wade AG, Leinonen EV, et al. A controlled, prospective, 1-year trial of citalopram in the treatment of panic disorder. J Clin Psychiatry 1998; 59: 528-34
280. Pohl RB, Wolkow RM, Clary CM. Sertraline in the treatment of panic disorder: a double-blind multicenter trial. Am J Psychiatry 1998; 155: 1189-95
281. Pollack MH, Otto MW, Worthington JJ, et al. Sertraline in the treatment of panic disorder: a flexible-dose multicenter trial Arch Gen Psychiatry 1998; 55: 1010-6
282. Den Boer JA. Pharmacotherapy of panic disorder: differential efficacy from a clinical viewpoint. J Clin Psychiatry 1998; 59 Suppl. 8: 30-6
283. Gorman JM. Treatment of generalized anxiety disorder. J Clin Psychiatry 2002; 63 Suppl. 8: 17-23
284. Pollack MH, Zaninelli R, Goddard A, et al. Paroxetine in the treatment of generalized anxiety disorder: results of a placebo-controlled, flexible-dosage trial. J Clin Psychiatry 2001; 62: 350-7
285. Rocca P, Fonzo V, Scotta M, et al. Paroxetine efficacy in the treatment of generalized anxiety disorder. Acta Psychiatr Scand 1997; 95: 444-50
286. Varia I, Rauscher F. Treatment of generalized anxiety disorder with citalopram. Int Clin Psychopharmacol 2002; 17: 103-7
287. Brunello N, Davidson JRT, Deah M, et al. Posttraumatic stress disorder: diagnosis and epidemiology, comorbidity and social consequences, biology and treatment. Neuropsychobiology 2001; 43: 150-62
288. Davidson JRT. Recognition and treatment of posttraumatic stress disorder. JAMA 2002; 286: 584-8
289. Yehuda R. Post-traumatic stress disorder. N Engl J Med 2002 Jan 10; 346: 108-14
290. Hageman I, Andersen HS, Jorgensen MB. Post-traumatic stress disorder: a review of psychobiology and pharmacotherapy. Acta Psychiatr Scand 2001; 104: 411-22
291. Martenyi F, Brown EB, Zang H, et al. Fluoxetine versus placebo in post-traumatic stress disorder. J Clin Psychiatry 2002; 63: 199-206
292. Connor KM, Sutherland SM, Tupler LA, et al. Fluoxetine in post-traumatic stress disorder: randomized double-blind study. Br J Psychiatry 1999; 175: 17-22
293. Stahl SM, Gergel I, Li D. Escitalopram in the treatment of panic disorder: a randomized, double-blind, placebo-controlled trial. J Clin Psychiatry 2003; 64: 1322-7
294. Rapaport MH, Endicott J, Clary CM. Posttraumatic stress disorder and quality of life: results across 64 weeks of sertraline treatment. J Clin Psychiatry 2002; 63: 59-65
295. Tucker P, Zaninelli R, Yehuda R, et al. Paroxetine in the treatment of chronic posttraumatic stress disorder: results of a placebo-controlled, flexible-dosage trial. J Clin Psychiatry 2001; 62: 860-8
296. Stein DJ, Davidson J, Seedat S, et al. Praoxetine in the treatment of post-traumatic stresss disoder: pooled analysis of placebo-controlled studies. Expert Opin Pharmacother 2003; 4: 1829-38
297. Brady KT, Clary CM. Affective and axiety comorbidity in posttraumatic stress disorder treatment trials of sertraline. Compr Psychiatry 2003; 44: 360-9
298. Cross National Collaborative Panic Study, Second Phase Investigators. Drug treatment of panic disorder. Br J Psychiatry 1992; 160: 191-202
299. Andersch S, Rosenberg NK, Kullingsjo H, et al. Efficacy and safety of alprazolam, imipramine, and placebo in treating panic disorder: a Scandinavian multicenter study. Acta Psychiatr Scand 1991; 365: 18-27
300. Caillard V, Rouillon F, Viel JF, et al. Comparative effects of low and high doses of clomipramine and placebo in panic disorder: a double-blind controlled study. French University Antidepressant Group. Acta Psychiatr Scand 1999; 99: 51-8
301. Ribiero L, Busnello JV, Kauer-Sant' Anna M, et al. Mirtazapine versus fluoxetine in the treatment of panic disorder. Braz J Med Biol Res 2001; 34: 1303-7
302. Papp LA, Sinha SS, Martinez JM, et al. Low-dose venlafaxine treatment in panic disorder. Psychopharmacol Bull 1998; 34: 207-9
303. Pollack MH, Worthington JJ, Otto MW, et al. Venlafaxine for panic disorder: results from a double-blind, placebo-controlled study. Psychopharmacol Bull 1996; 32: 667-70
304. Papp LA, Coplan JD, Martinez JM, et al. Efficacy of open-label nefazodone treatment in patients with panic disorder. J Clin Psychopharmacol 2000; 20: 544-6
305. Bystritsky A, Rosen R, Suri R, et al. Pilot open-label study of nefazodone in panic disorder. Depress Anxiety 1999; 10: 137-9
306. Mavissakalian MM, Perel J, Bowler K, et al. Trazodone in the treatment of panic disorder and agorophobia with panic attacks. Am J Psychiatry 1987; 144: 785-7
307. Charney DS, Woods SW, Goodman WK, et al. Drug treatment of panic disorder: the comparative efficacy of imipramine, alprazolam, and trazodone. J Clin Psychiatry 1986; 47: 580-6
308. Gelenberg AJ, Lydiard RB, Rudolph RL, et al. Efficacy of venlafaxine extended-release capsules in nondepressed outpatients with generalized anxiety disorder: a 6-month randomized controlled trial. JAMA 2000; 283: 3082-8
309. Rickels K, Pollack MH, Sheehan DV, et al. Efficacy of extended-release venlafaxine in nondepressed outpatients with generalized anxiety disorder. Am J Psychiatry 2000; 157: 968-74
310. Davidson JRT, DuPont RL, Hedges D, et al. Efficacy, safety, and tolerability of venlafaxine extended release and buspirone in outpatient with generalized anxiety disorder. J Clin Psychiatry 1999; 60: 528-35
311. Rolland PD, Kablinger AS, Brannon GE, et al. Treatment of generalized anxiety disorder with venlafaxine XR: a randomized, double-blind trial in comparison with buspirone and placebo. Clin Drug Invest 2000; 19: 163-5
312. Hedges DW, Reimherr FW, Strong RE, et al. An open trial of nefazodone in adult patients with generalized anxiety disorder. Psychopharmacol Bull 1996; 32: 671-6
313. Rickels K, Downing R, Schweizer E, et al. Antidepressants for the treatment of generalized anxiety disorder: a placebo-controlled comparison of imipramine, trazodone, and diazepam. Arch Gen Psychiatry 1993; 50: 884-95
314. Goodnick PJ, Puig A, DeVane CL, et al. Mirtazapine n major depression with comorbid generalized anxiety disorder. J Clin Psychiatry 1999; 60: 446-8
315. Quitkin FM, Taylor BP, Kremer C. Does mirtazapine have a more rapid onset than SSRIs? J Clin Psychiatry 2001; 62: 358-61
316. Hoehn-Saric R. Generalized anxiety disorder: guidelines for diagnosis and treatment. CNS Drugs 1998; 9: 85-98
317. Gillin JC, Smith-Vaniz A, Schnierow B, et al. An open-label, 12-week clinical and sleep EEG study of nefazodone in chronic combat-related posttraumatic stress disorder. J Clin Psychiatry 2001; 62: 789-96
318. Zisook S, Chentsova-Dutton YE, Smith-Vaniz A, et al. Nefazodone in patients with treatment-refractory posttraumatic stress disorder. J Clin Psychiatry 2000; 61: 203-8
319. Davis LL, Nugent AL, Murray J, et al. Nefazodone treatment for chronic posttraumatic stress disorder: an open trial. J Clin Psychopharmacol 2000; 20: 159-64
320. Hidalgo R, Hertzberg MA, Mellman T, et al. Nefazodone in post-traumatic stress disorder: results from six open label trials. Int Clin Psychopharmacol 1999; 14: 61-8
321. Canive JM, Clark RD, Calais LA, et al. Bupropion treatment in veterans with posttraumatic stress disorder: an open study. J Clin Psychopharmacol 1998; 18: 379-83
322. Connor KM, Davidson JRT, Weisler RH, et al. A pilot study of mirtazapine in post-traumatic stress disorder. Int Clin Psychopharmacol 1999; 14: 29-31
323. Hertzberg MA, Feldman ME, Beckham JC, et al. Trial of trazodone for posttraumatic stress disorder using a multiple baseline group design. J Clin Psychopharmacol 1996; 16: 294-8
324. Ballenger JC, Davidson JRT, Lecrubier Y, et al. Consensus statement on posttraumatic stress disorder from the International Consensus Group on Depression and Anxiety. J Clin Psychiatry 2000; 61 Suppl. 5: 60-6
325. Davidson JRT. Pharmacotherapy of posttraumatic stress disorder: treatment options, long-term follow up, and predictors of outcome. J Clin Psychiatry 2000; 61 Suppl. 5: 52-6
326. Wise MG, Hilty DM, Cerda CM, et al. Delirium. In: Wise MG, Rundell JR, editors. The American Psychiatric Publishing textbook of consultation-liaison psychiatry: psychiatry in the medically ill. 2nd ed. Washington, DC: American Psychiatric Publishing Inc, 2002: 257-72
327. Crone CC, Wise TN. Psychiatric aspects of transplantation: III. postoperative issues. Crit Care Nurse 1999; 19: 28-38
328. Stukas AA, Dew MA, Switzer GE, et al. PTSD in heart transplant recipients and their primary family caregivers. Psychosomatics 1999; 40: 212-21
329. Dew MA, Kormos RL, Roth LH, et al. Early post-transplant medical compliance and mental health predict physical morbidity and mortality one to three years after heart transplantation. J Heart Lung Transplant 1999 Jun; 18 (6): 549-62
330. Dew MA, Roth LH, Schulberg HC, et al. Prevalence and predictors of depression and anxiety-related disorder during the year after heart transplantation. Gen Hosp Psychiatry 1996; 18 Suppl. 1: 48S-61S